159 related articles for article (PubMed ID: 32338875)
21. Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience.
Uysal A; Akad Soyer N; Özkan M; Şahin F; Vural F; Töbü M; Tombuloğlu M; Saydam G
Turk J Med Sci; 2018 Feb; 48(1):80-83. PubMed ID: 29479960
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
[TBL] [Abstract][Full Text] [Related]
23. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
24. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
25. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
26. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
27. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
28. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Sandy EB; Weerasinghe C; Terjanian T
J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
[TBL] [Abstract][Full Text] [Related]
29. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
30. Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.
Taha MS; Cresswell GM; Park J; Lee W; Ratliff TL; Yeo Y
Nano Lett; 2019 Nov; 19(11):8333-8341. PubMed ID: 31657935
[TBL] [Abstract][Full Text] [Related]
31. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
33. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
Piotrowicz RS; Damaj BB; Hachicha M; Incardona F; Howell SB; Finlayson M
Mol Cancer Ther; 2011 Nov; 10(11):2072-82. PubMed ID: 21885863
[TBL] [Abstract][Full Text] [Related]
34. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
35. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
[TBL] [Abstract][Full Text] [Related]
36. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
37. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.
Wang Q; Lin Z; Wang Z; Ye L; Xian M; Xiao L; Su P; Bi E; Huang YH; Qian J; Liu L; Ma X; Yang M; Xiong W; Zu Y; Pingali SR; Xu B; Yi Q
Blood; 2022 Jan; 139(1):59-72. PubMed ID: 34411225
[TBL] [Abstract][Full Text] [Related]
38. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M
Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy.
Wu XL; Kim JH; Koo H; Bae SM; Shin H; Kim MS; Lee BH; Park RW; Kim IS; Choi K; Kwon IC; Kim K; Lee DS
Bioconjug Chem; 2010 Feb; 21(2):208-13. PubMed ID: 20073455
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
Bilotti E
Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]